September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
PRELIMINARY RESULTS OF A RANDOMIZED CONTROLLED TRIAL COMPARING TRANSEPITHELIAL CORNEAL CROSS-LINKING WITH IONTOPHORESIS AND STANDARD CROSS-LINKING IN PATIENTS WITH PROGRESSIVE KERATOCONUS
Author Affiliations & Notes
  • sebastiano serrao
    Fondazione Bietti Roma, Rome, Italy
  • Giuseppe Lombardo
    Consiglio Nazionale delle Ricerche, Istituto per i Processi Chimico-Fisici, Messina, Italy
  • Marianna Rosati
    Fondazione Bietti Roma, Rome, Italy
  • domenico schiano lomoriello
    Fondazione Bietti Roma, Rome, Italy
  • Marco Lombardo
    Fondazione Bietti Roma, Rome, Italy
  • Footnotes
    Commercial Relationships   sebastiano serrao, None; Giuseppe Lombardo, None; Marianna Rosati, None; domenico schiano lomoriello, None; Marco Lombardo, None
  • Footnotes
    Support  PON_0100110
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2892. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      sebastiano serrao, Giuseppe Lombardo, Marianna Rosati, domenico schiano lomoriello, Marco Lombardo; PRELIMINARY RESULTS OF A RANDOMIZED CONTROLLED TRIAL COMPARING TRANSEPITHELIAL CORNEAL CROSS-LINKING WITH IONTOPHORESIS AND STANDARD CROSS-LINKING IN PATIENTS WITH PROGRESSIVE KERATOCONUS. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2892.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To report the clinical outcomes 3 months after transepithelial corneal cross-linking (CL) using iontophoresis (T-ionto CL) in comparison with standard corneal cross-linking in eyes with progressive keratoconus.

Methods : Transepithelial CL using iontophoresis was performed using hypotonic ethylenediaminetetraacetic acid and trometamol enriched dextran-free 0.1% riboflavin solution and UV-A irradiation with 10 mW/cm2 UV-A device for 9 minutes. Standard CL was performed according to the “Dresden protocol” using 20% dextran enriched 0.1% riboflavin solution and UV-A irradiation with 3 mW/cm2 UV-A device for 30 minutes. The primary outcome measure was the maximum simulated keratometry value (Kmax). Other outcome measures were best spectacle corrected visual acuity (BSCVA; logMAR units), manifest refraction, central corneal thickness (CCT; using AS-OCT) and endothelial cell density (ECD; no-contact specular microscopy). Follow-up visits were scheduled at 3 and 7 days, 1- and 3-months.

Results : Thirty-four eyes with progressive keratoconus were recruited in the study and randomized in two groups: T-ionto CL (22 eyes) and standard CL (12 eyes). At 3 months, Kmax decreased from 54.7±4.0 D to 54.2±3.9 D (P=0.11) and from 54.7±4.2 D to 54.3±4.7 D (P=0.33) in the study and in control group respectively. At 3 months, BSCVA improved from 0.12±0.20 LogMAR to 0.04±0.10 LogMAR (P=0.01) after T-ionto CL; no change in BSCVA was found after standard CL (from 0.03±0.09 LogMAR to 0.06±0.09 LogMAR; P=0.26). The manifest spherical equivalent refraction changed averagely by +0.57 D (P=0.02) and +0.22 D (P=0.26) in the T-ionto CL and standard CL groups respectively at 3 months. CCT ranged from 484±37 µm to 486±28 µm (P=0.72) and from 494±34 µm to 484±38 µm (P=0.15) in the study and control group respectively from preoperatively to 3 months. ECD count did not change during 3 months, except for a drop at day 3 in the control group, due to posterior stromal edema in 60% of cases. There was 1 eye in the control group with peripheral corneal infiltrates that did not affect the 3 months visual acuity.

Conclusions : The 3-months results are demonstrating that T-ionto CL is safe with comparable efficacy to conventional treatment for halting keratoconus progression in the short term period.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×